Likewise, another study found that lenalidomide, in combination with CD19-CAR-T-cell therapy, induced IFN-γ production; as a result, it caused elevated activity and infiltration of T cells in TME and reduced tumor burden in mice [172]. Here, CD19 is linked to neoplasm.